"Additionally, Cynata is responding to enquiries and is in active discussions with international pharmaceutical
companies and other parties about the potential of its Cymerus MSCs to be a useful adjunct in the management of
patients with serious and ongoing issues associated with COVID-19 infection."
Ann: Market Update & Additional A$618k R&D Tax Refund, page-2
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.005(1.54%) |
Mkt cap ! $57.48M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.5¢ | 31.0¢ | $34.98K | 109.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4417 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
31.5¢ |
Change
-0.005 ( 1.56 %) |
||||
| Open | High | Low | Volume | ||
| 34.0¢ | 34.0¢ | 31.0¢ | 58490 | ||
| Last updated 15.51pm 30/05/2024 ? | |||||
| CYP (ASX) Chart |